To protect patient access to current and future treatments for a range of serious conditions, such as cancer, Alzheimer's disease, HIV/AIDS, Parkinson's disease, and sickle cell disease, among numerous others.

SA 5389. Mr. MARSHALL submitted an amendment intended to be proposed
to amendment SA 5194 proposed by Mr. Schumer to the bill H.R. 5376, to
provide for reconciliation pursuant to title II of S. Con. Res. 14;
which was ordered to lie on the table as follows:

At the end of title I, add the following:

Subtitle E--Ensuring Patient Access to Drugs and Biological Products
That Treat Serious Conditions

SEC. 14001. ENSURING PATIENT ACCESS TO DRUGS AND BIOLOGICAL
PRODUCTS THAT TREAT SERIOUS CONDITIONS.

Section 1192(e)(3) of the Social Security Act, as added by
section 11001, is amended by adding at the end the following
new subparagraphs:
``(D) Six protected classes.--A covered part D drug in a
category or class that is identified under section 1860D-
4(b)(3)(G)(iv).
``(E) Breakthrough therapies.--A drug or biological product
designated under section 506(a) of the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. 356(a)) as a breakthrough therapy
and approved under section 505 of such Act (21 U.S.C. 355) or
section 351 of the Public Health Service Act (42 U.S.C.
262).''.

SEC. 14002. REDUCTION OF ADDITIONAL IRS FUNDING FOR
ENFORCEMENT AND OPERATIONS.

Section 10301(a)(1)(A)(i) of this Act is amended--
(1) in subclause (II), by striking ``$45,637,400,000'' and
inserting ``$10,326,400,000''; and
(2) in subclause (III), by striking ``$25,326,400,000'' and
inserting ``$326,400,000''.
______